Cardiac involvement in coronavirus disease 2019 assessed by cardiac magnetic resonance imaging: a meta-analysis

Shingo Kato1,2 · Mai Azuma2 · Kazuki Fukui2 · Sho Kodama2 · Naoki Nakayama2 · Hideya Kitamura3 · Eri Hagiwara3 · Takashi Ogura3 · Nobuyuki Horita4 · Ho Namkoong5 · Kazuo Kimura6 · Kouichi Tamura7 · Daisuke Utsunomiya1

Received: 7 November 2021 / Accepted: 4 March 2022 / Published online: 16 March 2022
© Springer Japan KK, part of Springer Nature 2022

Abstract
In this systematic review and meta-analysis, we sought to evaluate the prevalence of cardiac involvement in patients with COVID-19 using cardiac magnetic resonance imaging. A literature review was performed to investigate the left ventricular (LV) and right ventricular (RV) ejection fraction (EF), the prevalence of LV late gadolinium enhancement (LGE), pericardial enhancement, abnormality on T1 mapping, and T2 mapping/T2-weighted imaging (T2WI), and myocarditis (defined by modified Lake Louis criteria). Pooled mean differences (MD) between COVID-19 patients and controls for LVEF and RVEF were estimated using random-effects models. We included data from 10,462 patients with COVID-19, comprising 1,010 non-athletes and 9,452 athletes from 29 eligible studies. The meta-analysis showed a significant difference between COVID-19 patients and controls in terms of LVEF [MD = −2.84, 95% confidence interval (CI) −5.11 to −0.56, p < 0.001] and RVEF (MD = −2.69%, 95% CI −4.41 to −1.27, p < 0.001). However, in athletes, no significant difference was identified in LVEF (MD = −0.74%, 95% CI −2.41 to −0.93, p = 0.39) or RVEF (MD = −1.88%, 95% CI −5.21 to 1.46, p = 0.27). In non-athletes, the prevalence of LV LGE abnormalities, pericardial enhancement, T1 mapping, T2 mapping/T2WI, myocarditis were 27.5% (95%CI 17.4–37.6%), 11.9% (95% CI 4.1–19.6%), 39.5% (95%CI 16.2–62.8%), 38.1% (95%CI 19.0–57.1%) and 17.6% (95%CI 6.3–28.9%), respectively. In athletes, these values were 10.8% (95%CI 2.3–19.4%), 35.4% (95% CI −3.2 to 73.9%), 5.7% (95% CI −2.9 to 14.2%), 1.9% (95% CI 1.1–2.7%), 0.9% (0.3–1.6%), respectively. Both LVEF and RVEF were significantly impaired in COVID-19 patients compared to controls, but not in athletes. In addition, the prevalence of myocardial involvement is not negligible in patients with COVID-19.

Keywords COVID-19 · Cardiac involvement · Meta-analysis

Abbreviations

ACE 2 Angiotensin converting enzyme 2
COVID-19 Coronavirus disease 2019
CI Confidence interval
CK-MB Creatinine kinase myocardial band
CMR Cardiac magnetic resonance
SARS-CoV-2 Severe acute respiratory syndrome-coronavirus-2
LGE Late gadolinium enhancement
LV Left ventricular
MD Mean difference
MRI Magnetic resonance imaging
RV Right ventricular
T2WI T2 weighted image
Introduction

Coronavirus disease-2019 (COVID-19), caused by the novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has become a global pandemic [1]. Cardiac involvement is a serious complication in patients with COVID-19 and elevated serum troponin levels are observed in 17–36% of the COVID-19 patients [2]. Cardiac involvement includes a variety of clinical manifestations, such as acute myocardial injury, heart failure, pulmonary embolism, myocarditis/pericarditis, and ventricular arrhythmias [3]. The mechanism of cardiac involvement is uncertain, but it may be related to endothelial dysfunction, systemic cytokine-mediated injury, or stress-related cardiomyopathy [4, 5]. Importantly, COVID-19 patients with cardiac involvement have worse clinical outcomes than those without cardiac involvement [6]. Therefore, elucidation of the imaging characteristics indicative of cardiac involvement may contribute to effective risk stratification for patients with COVID-19.

Cardiac magnetic resonance (CMR) imaging has emerged as a non-invasive imaging modality to accurately assess ventricular function, myocardial edema, and myocardial injury. Recently, several studies have demonstrated the utility of CMR imaging in detecting cardiac involvement in COVID-19 [7–11]. However, heterogeneity of data exists among these studies regarding the severity and prevalence of cardiac involvement detected by CMR imaging. Therefore, this study aimed to determine the prevalence of cardiac abnormalities detected by CMR imaging in patients with COVID-19.

Materials and methods

Literature search

The electronic database search formulas for PubMed, Web of Science Core Collection, Cochrane Advanced Search, and EMBASE are listed in the appendix (Supplemental material). Databases from the end of 2021 were searched on January 20, 2022. In addition, two review authors (SK and MA) independently performed additional manual searches. Potential research articles were screened and subjected to full-test scrutiny (KS, MA). When two authors could not resolve a disagreement, a third author participated in the discussion. The protocol for this systematic review, which complies with the Meta-analyses of Observational Studies in Epidemiology guidelines, has been registered on the website of the University Medical Informatics Network (UMIN000044237UMIN).

Eligibility criteria and outcomes

Publications including the CMR data of patients recovered from COVID-19 were screened. All study design types were used, including prospective studies, retrospective studies, and case series. However, we did not include case reports or case series with fewer than five cases because they are not suitable for estimating the frequency of adverse events. Eligible papers were written in English and both full articles and conference abstracts were accepted. Key study characteristics, such as author name, publication year, country of origin, and the number of COVID-19 patients, were extracted by two review authors (SK, MA). In addition, the outcome data were read by the authors. The main outcomes were mean averages of LVEF and RVEF, the prevalence of LV LGE, pericardial enhancement, abnormal T1 (native T1 time) mapping, abnormal T2 mapping/ T2 weighted image (T2WI), and myocarditis (defined by the modified Lake Louise criteria) [12]. LVEF and RVEF were compared between COVID-19 patients and controls. If one study had two cohorts (e.g., symptomatic vs. asymptomatic; LGE (+) vs. LGE (-)), we used patient data with abnormal findings and compared them to those of the controls (e.g., Brito 2021 symptomatic; Altay 2021 LGE (+); Chen 2021 troponin (+)). As the prevalence of cardiac involvement may differ between non-athletes and athletes, we analyzed these populations separately. In addition, the multisystem inflammatory syndrome is a different pathophysiologic response to SARS-CoV-2 exposure and is different (with a much different time course) from the convalescent phase post-acute COVID-19. We did not include multisystem inflammatory syndromes in our analysis [13].

Statistical analysis

The frequency of each cardiac abnormality was pooled using a random-model meta-analysis using the generic inverse variance method (RevMan ver 5.4. Cochrane Collaboration, London, UK). The standard error was calculated using the Agrestia method [14]. Random model meta-analysis was performed using RevMan 5.41 (Cochrane Collaboration, London, UK). LVEF and RVEF were expressed as median (range) in both COVID-19 patients and controls. Heterogeneity was indicated by I², with 0% indicating no heterogeneity and 100% indicating the strongest heterogeneity.
Results

Study characteristics

Of the 738 candidate studies, we finally selected 29 eligible reports [7–11, 15–38] (Fig. 1). Four of the studies presented two cohorts [8, 10, 21, 31]; therefore, we included a total of 33 independent cohorts. Among the 29 included studies, nine were from the USA [8, 15, 20, 22, 24, 32, 36–38], six were from China [10, 11, 16, 18, 21, 30], three each from the UK [19, 22, 26] and Germany [7, 23, 28, 35], two each from Italy [9, 27] and Turkey [29, 31], and one each from Poland [17], Norway [34], Hungary [33] and Spain [25]. The publication year was 2020 or 2021 (Table 1). Ten studies enrolled athletes recovered from COVID-19 [8, 15, 17, 20, 24, 32, 36–38] and one study enrolled suspected myocarditis with COVID-19 [9]. Finally, 10,462 patients with COVID-19, including 1,010 non-athletes and 9,452 athletes, and 746 controls were included in our analysis. A 1.5 T MR scanner was used in 15 studies [8, 9, 11, 15, 17, 22–26, 28, 29, 33–35] and a 3.0 T MR scanner was used in six studies [7, 10, 16, 18, 21, 30]. Both 1.5 T and 3.0 T scanners were used in one study [20] and data regarding MR scanners were not provided in seven studies [19, 27, 31, 32, 36–38]. As the myocardial native T1 time substantially differs between different magnetic field strengths and sequences [39], we investigated the number patients with abnormal T1 time, rather than those with absolute value of native T1 time, among the nine studies presenting the prevalence of patients with abnormal native T1 times [7–9, 11, 17, 22, 26, 27, 32].

Meta-analysis of CMR imaging findings in patients with COVID-19

LVEF and RVEF were measured in 27 cohorts of 1414 COVID-19 patients. In COVID-19 patients, the median LVEF was 60.3% (range: 50.3–67.1%), and the median RVEF was 54.3% (range: 36.5–61.1%). In non-athlete, the median LVEF was 60.8% (range: 50.3–67.0%), and the median RVEF was 54.7% (range: 36.5–61.1%). In athlete, the median LVEF was 60.0% (range: 57.0–60.3%), and the median RVEF was 54.6% (range: 53.0–56.0%). In the controls, the median LVEF and RVEF were 61.3% (range: 57.0–67.0%) and 57.7% (range: 45.0–64.0%), respectively. The meta-analysis showed a significant difference between COVID-19 patients and controls in terms of LVEF [mean difference (MD) = −2.84, 95% confidence interval (CI) −5.11 to −0.56, p < 0.001] and RVEF (MD = −2.69%, 95% CI −4.41, −1.27, p < 0.001) (Fig. 2). However, in athletes, no significant differences were identified in LVEF (MD = −0.74%, 95% CI −2.41 to −0.93, p = 0.39) and RVEF (MD = −1.88%, 95% CI −5.21 to 1.46, p = 0.27) (Fig. 3). Figure 4 illustrates the results of the meta-analysis of LGE of LV myocardium, pericardial enhancement, abnormal T1 mapping, and T2 mapping/T2WI in non-athletes.

Fig. 1 PRISMA flow diagram
| Cohort     | Country | MRI machine | Number of patients | Patient characteristics                                                                 | Time from diagnosis (symptom) to MRI | LVEF, % (N%) | RVEF, % (N%) | LGE of LV, N (%) | Abnormal T1 map, N (%) | Abnormal T2 map/T2WI, N (%) | Pericardial enhancement, N (%) | Myocarditis, N (%) |
|------------|---------|-------------|--------------------|-----------------------------------------------------------------------------------------|--------------------------------------|-------------|-------------|-----------------|----------------------|--------------------------|-------------------------------|---------------------|
| Brito 2021 | USA     | 1.5 T       | 37                 | Asymptomatic; 11 symptomatic                                                           | 27 days                              | 59.09 (54.79–61.64)% in asymptomatic; 60.32 (56.66–63.33)% in symptomatic | 54.60% (47.55–59.77) in asymptomatic; 51.32% (50.82–57.22) in symptomatic | 0 (0%) in asymptomatic; 1 (3%) in symptomatic | 1 (9%) in asymptomatic; 8 (22%) in symptomatic | 9 (82%) in asymptomatic; 10 (27%) in symptomatic | 0 (0%) |
| Clark 2021 | USA     | 1.5 T       | 59                 | COVID-19-positive athletes                                                              | 21.5 days                            | 60 (56–63)% | 53 (50–56)% | 1 (2%)           | N/A                  | N/A                      | 1 (2%)                        | 4 (15%)            |
| Huang 2020 | China   | 3.0 T       | 26                 | CMR abnormal; 11 CMR normal                                                              | 48 days in CMR abnormal; 50 days in CMR normal | 60.7 ± 6.4% in CMR abnormal; 64.3 ± 5.8% in CMR normal | 36.5 ± 6.1% in CMR abnormal; 41.1 ± 8.6% in CMR normal | 8 (26%) in CMR abnormal; N/A in CMR normal | N/A                  | N/A                      | N/A                        | N/A                  |
| Li 2021    | China   | 3.0 T       | 40                 | Patients recovered from COVID-19                                                         | 158 days                             | 62.6 ± 5.2% | 54.7 ± 5.8% | 1 (3%)           | N/A                  | N/A                      | N/A                        | N/A                  |
| Pan 2021   | China   | 3.0 T       | 21                 | Patients recovered from COVID-19                                                         | N/A                                  | 61.6 ± 6.5% | 54.7 ± 7.1% | N/A             | N/A                  | N/A                      | N/A                        | N/A                  |
| Puntmann 2020 | Germany | 3.0 T       | 100                | Patients recovered from COVID-19                                                         | 71 days                              | 57 ± 6%    | 54 ± 7%    | 32 (32%)         | 73 (73%)             | 60 (60%)                  | 22 (22%)                    | N/A                  |
| Raisi-Estabrigh 2021 | UK     | N/A         | 70                 | UK Biobank participants with positive COVID-19 PCR                                       | N/A                                  | 59.6 ± 6.5% | 61.1 ± 6.2% | N/A             | N/A                  | N/A                      | N/A                        | N/A                  |
| Wang 2021  | China   | 3.0 T       | 44                 | Patients recovered from COVID-19                                                         | 100.8 days in LGE positive; 103.3 days in LGE negative | 64.3 ± 5.9% in LGE positive; 62.2 ± 4.4% in LGE negative | 59.5 ± 8.6% in LGE positive; 56.6 ± 8.3% in LGE negative | 13 (29.5%) | N/A                  | N/A                      | N/A                        | N/A                  |
| Esposito 2020 | Italy  | 1.5 T       | 10                 | COVID-19 patients suspected for myocarditis                                           | N/A                                  | N/A        | N/A        | 3 (30%)          | 8 (100%)             | 8 (100%)                  | N/A                        | 8 (80%)             |
| Malek 2021 | Poland  | 1.5 T       | 26                 | Elite athletes positive for COVID-19 PCR                                               | 32 days                              | 61 (60–62)% | 59 (57–60)% | 1 (4%)           | 0 (0%)               | 4 (15%)c                 | N/A                        | 0 (0%)               |
| Ng 2020    | China   | 1.5 T       | 16                 | Patients recovered from COVID-19                                                         | 56 days                              | 59 (56–65)% | 53 (48–57)% | 3 (19%)          | 4 (25%)              | 1 (5%)                   | N/A                        | N/A                  |
| Cohort          | Country   | MRI machine | Number of patients | Patient characteristics                                                                 | Time from diagnosis (symptom) to MRI | LVEF, % | RVEF, % | LGE of LV, N (%) | Abnormal T1 map, N (%) | Abnormal T2 map/T2WI, N (%) | Pericardial enhancement, N (%) | Myocarditis, N (%) |
|-----------------|-----------|-------------|--------------------|----------------------------------------------------------------------------------------|------------------------------------|---------|---------|-----------------|------------------------|-------------------------------|-------------------------------|------------------|
| Starekova 2021  | USA       | 1.5 T or 3.0 T | 145               | Competitive student athletes recovered from COVID-19                                    | 16 days                           | 58 ± 5% | 54 ± 6% | 42 (29%)        | N/A                    | N/A                           | N/A                           | 2 (1.4%)         |
| Altay 2021      | Turkey    | N/A         | 15                | Symptomatic patients with COVID-19                                                       | 81 days                           | 51 ± 16% | 45 ± 12% | 7 (46%)         | N/A                    | N/A                           | N/A                           | N/A              |
| Breithart 2021  | Germany   | 1.5 T       | 56                | Post COVID-19 patients without previous heart diseases                                  | 71 days                           | 62.3 ± 5.0% | N/A | 7 (1.5%) | N/A | N/A | N/A | N/A | 1 (2%) |
| Çakmak 2021     | Turkey    | 1.5 T       | 64                | Patients with cardiac symptoms after recovering from COVID-19                           | 71 days                           | 67 (58–76) % | N/A | 46 (69%) | N/A | N/A | N/A | 11 (17%) | 0 (0%) |
| Chen 2021       | China     | 3.0 T       | 25                | Confirmed COVID-19 and at least one marker of cardiac involvement                       | 6.7 ± 5.7 days                    | 64.6 ± 4.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Daniels 2021    | USA       | N/A         | 1597              | Athletes with COVID-19                                                                  | N/A                               | N/A | N/A | 36 (23%) | 5 (0.3%) | N/A | N/A | 37 (2.3%) |
| Galea 2021      | Italy     | N/A         | 27                | Active COVID-19 and suspected cardiac involvement                                       | 20 (13.5–31.5) days               | 50.3 ± 7.2% | 48.8 ± 8.2% | 12 (44.4%) | 11 (40.7%) | 14 (51.9%) | 2 (7.4%) | 9 (33%) |
| Joy 2021        | UK, USA   | 1.5 T       | 149               | Patients from COVID consortium                                                         | N/A                               | 67.1 ± 4.9% | N/A | 13 (8.7%) | 6 (4%) | 9 (6%) | N/A | N/A | N/A |
| Kotecha 2021    | UK        | 1.5 T       | 148               | All patients admitted with a diagnosis of COVID-19                                      | 68 (39–103) days                  | 67 ± 11% | 61 ± 9% | 70 (47.3%) | 19 (12.8%) | 4 (2.7%) | N/A | 40 (27%) |
| Kravchenko 2021 | Germany   | 1.5 T       | 41                | SARS-CoV-2 infection who had persistent CCS symptoms                                   | 103 (88–158) days                 | 62 ± 5% | N/A | 3 (7.3%) | N/A | N/A | N/A | 0 (0%) |
Table 1 (continued)

| Cohort     | Country   | MRI machine | Number of patients | Patient characteristics                                      | Time from diagnosis (symptom) to MRI | LVEF, %     | RVEF, %     | LGE of LV, N (%) | Abnormal T1 map, N (%) | Abnormal T2 map/T2WI, N (%) | Pericardial enhancement, N (%) | Myocarditis, N (%) |
|------------|-----------|-------------|--------------------|-------------------------------------------------------------|-------------------------------------|------------|------------|------------------|------------------------|---------------------------|-----------------------------|-------------------|
| Myhre 2021 | Norway    | 1.5 T       | 58                 | Survivors from the prospective COVID MECH study             | 175 (105–217) days                 | 58.7 ± 7.4% | 57.3 ± 6.3% | N/A              | N/A                    | N/A                       | N/A                         | N/A                |
| Rajpal 2021 | USA       | 1.5 T       | 26                 | Competitive athletes referred to the sports medicine clinic after testing positive for COVID-19 | 11–53 days                         | N/A        | N/A        | 12 (46.2%)       | N/A                    | N/A                       | N/A                         | 4 (15%)           |
| Szabó 2021 | Hungary   | 1.5 T       | 147                | Athletes after SARS-CoV-2 infection                         | Median of 32 days                  | 57 (54–60)% | 56 (53–59)% | N/A              | N/A                    | N/A                       | N/A                         | 1 (0.6%)          |
| Tanaci 2021 | Germany   | 1.5 T       | 32                 | Persistent cardiac symptoms after a COVID-19 infection      | 95 ± 59 days                       | 62 ± 10%   | 54 ± 8%    | 6 (18.8%)        | N/A                    | N/A                       | 3 (9.4%)                     | 3 (9%)            |
| Urmeneta 2021 | Spain   | 1.5 T       | 57                 | Post-COVID-19 patients                                      | 81 ± 27 days, N/A                  | 61 ± 10%   | 60 ± 9%    | 13 (22.8%)       | N/A                    | N/A                       | 2 (3.5%)                     | N/A               |
| Martinez 2021 | USA     | N/A         | 789 (30 MRI performed) | Professional athletes                                       | N/A                                | N/A        | N/A        | N/A              | N/A                    | N/A                       | N/A                         | 5 (0.6%)          |
| Moulson 2021 | USA     | N/A         | 3018 (317 MRI performed) | Collegiate athletes                                        | N/A                                | N/A        | N/A        | N/A              | N/A                    | N/A                       | N/A                         | 21 (0.7%)         |
| Petek 2021   | USA       | N/A         | 3597 (44 MRI performed) | Young competitive athletes                                  | N/A                                | N/A        | N/A        | N/A              | N/A                    | N/A                       | N/A                         | 5 (0.1%)          |

LVEF and RVEF were presented as mean ± standard deviation or median (interquartile range). Myocarditis was diagnosed by modified Lake Louise Criteria.

COVID-19 coronavirus disease-2019, CMR cardiac magnetic resonance, IQR interquartile range, LGE late gadolinium enhancement, LVEF left ventricular ejection fraction, MRI magnetic resonance imaging, RVEF right ventricular ejection fraction, T2WI T2 weighted image.

*Three patients had abnormality in T2WI and one patient had abnormality in T2 mapping.
The prevalence of abnormalities of LV LGE, pericardial enhancement, T1 mapping, T2 mapping/T2WI were 27.5% (95%CI 17.4–37.6%), 11.9% (95%CI 4.1–19.6%), 39.5% (95%CI 16.2–62.8%), 38.1% (95%CI 19.0–57.1%), respectively (Fig. 4). In athletes, these values were 10.8% (95%CI 2.3–19.4%), 35.4% (95%CI 3.2–73.9%), 5.7% (95%CI 2.9 to 14.2%), 1.9% (95%CI 1.1–2.7%), respectively (Fig. 5). Figure 6 illustrates the prevalence of myocarditis, as defined by the modified Lake Louise criteria. The prevalence was 17.6% (95%CI 6.3–28.9%) for non-athletes and 0.9% (0.3–1.6%) for athletes.

Discussion

The main findings of this study are as follows: both LVEF and RVEF were significantly reduced in non-athlete patients with COVID-19 compared with controls, whereas both parameters were not significantly reduced in athletes with COVID-19. There was a moderate prevalence of LV LGE, pericardial enhancement, abnormal T1 mapping, T2 mapping/T2WI, and myocarditis (defined by modified Lake Louise criteria) in patients with COVID-19. The prevalence of cardiac involvement was substantially higher in non-athletes than in athletes. These results indicate that cardiac involvement is not negligible in patients with COVID-19, and CMR imaging is useful for the non-invasive detection of cardiac abnormalities in patients with COVID-19.

The incidence of myocardial injury assessed by serum troponin was reported as 17–36% and is associated with poor clinical outcomes in patients with COVID-19 [6, 40–43]. For example, a report from New York including 2736 COVID-19 patients demonstrated that 36% of patients showed elevation of serum troponin T (defined as >0.03 ng/dL), and even slight elevation of troponin I (>0.03–0.09 ng/dL) was a significant predictor of mortality in COVID-19 patients [42]. A report from Wuhan revealed that serum creatinine kinase myocardial band (CK-MB), myoglobin, troponin I, and NT-proBNP were significantly elevated in deceased COVID-19 patients compared with survivors of COVID-19 [6]. In addition, higher CK-MB, myoglobin, and troponin I levels were associated with higher mortality, especially in older patients [6]. Therefore, an accurate assessment of cardiac involvement is crucial in patients with COVID-19.

Several echocardiographic studies have described the characteristics of cardiac abnormalities in patients with COVID-19. Szekely et al. investigated the echocardiographic spectrum of cardiac disease in hospitalized patients with COVID-19 and reported that the prevalence of RV dilatation/dysfunction was 39%, LV systolic dysfunction was 10%, and LV diastolic dysfunction was 16% [44]. Another echocardiographic study showed that the prevalence of right ventricular dilatation (basal diastolic RV diameter > 41 mm) was 31% and a significant predictive factor for worse clinical outcomes in COVID-19 patients [45]. Giustino et al. reported that the prevalence of RV dysfunction, LV wall motion abnormality, LV diastolic dysfunction, and LV global dysfunction were 26.3%, 23.7%, 13.2%, and 18.4%, respectively [5]. As shown in these studies, RV dysfunction is prevalent and clinically important in patients with COVID-19; however, an important limitation of echocardiographic assessment of RV function is that the accuracy is substantially dependent on the operator’s skill. Furthermore, the reproducibility of measurement of RV function is limited owing to the complexity of the anatomy of the RV.

CMR imaging is an accurate and highly reproducible technique for assessing RV function [46]. Previous studies have demonstrated the clinical relevance of CMR-derived RV function. A study including 250 patients with dilated cardiomyopathy showed that impaired RVEF (defined as RVEF ≤ 45%) is a significant predictor of transplant-free survival and adverse heart failure outcomes [47]. RV volume by cine CMR imaging after correction for age, sex, and body surface area strongly predicted mortality in patients with idiopathic pulmonary hypertension [48]. CMR-derived RVEF is a powerful prognostic marker, even in patients with non-cardiac diseases, such as interstitial lung disease [49]. In our study, RVEF by cine MRI was significantly lower in patients with COVID-19 than in controls, suggesting that RV dysfunction is an important spectrum of cardiac disease in patients with COVID-19 (Fig. 2).

In our analysis, several pathological changes in the LV which cannot be evaluated using echocardiography were observed, such as decreased LVEF, LGE, abnormal native T1 time, and T2 time/T2WI. These findings may be related to myocardial edema, necrosis, and fibrosis caused by SARS-CoV-2 infection [2]. Recently, an update of the CMR imaging diagnostic criteria for myocardial inflammation in patients with suspected acute myocardial inflammation has been published (modified Lake Louise criteria) [12]. These criteria include T2-based criteria (global or regional increase in myocardial T2 relaxation time or an increased signal intensity in T2WI) and T1-based criteria (increased myocardial T1, extracellular volume, or LGE), and maybe useful for evaluating myocarditis caused by COVID-19. Furthermore, the presence of LGE is associated with poor clinical outcomes in patients with acute myocarditis [50], indicating that the presence of LV LGE has the potential to effectively risk-stratify patients with COVID-19 suspected myocarditis. Further studies are necessary to clarify whether this is the case.

The precise mechanisms underlying cardiac disease in COVID-19 patients remain unclear. Direct viral infection, oxygen supply–demand imbalance (type 2 myocardial infarction), inflammation-related injury, coronary plaque rupture (type 1 myocardial infarction), microvascular...
dysfunction/thrombosis, and stress cardiomyopathy are possible pathophysologies [2]. The angiotensin-converting enzyme 2 (ACE2) receptor may play an important role in COVID-19. SARS-CoV-2 is a single-stranded ribonucleic acid virus whose outer membrane spike protein binds with high affinity to the ACE2 receptor. Because ACE2 is primarily related to the conversion of angiotensin II to angiotensin 1-7, decreased ACE2 receptor density and impairment of ACE2 activity leads to an accumulation of angiotensin II, which results in vasoconstriction, inflammation, and fibrosis [2]. In another study, endothelial cell infection and endotheliitis of the kidney, small bowel, and lung tissue were demonstrated histopathologically [4]. For RV dysfunction, increased afterload following lung injury or hypoxemia, and RV ischemia due to hypoperfusion may be important pathophysologies [51]. Further studies are required to confirm these points.

This meta-analysis had some limitations. First, the number of studies analyzed was small, and a multicenter study has not been published in this field. Second, we could not compare absolute T1 and T2 times between COVID-19 patients and controls, as these values substantially differ between different magnetic field strengths and sequences. Third, the inclusion criteria of each study were substantially variable; therefore, selection bias was not negligible. A large-scale prospective multicenter study will be required to address these limitations. Fourth, it should be noted that RVEF assessment is often less robust even with CMR imaging and more subjective with LVEF assessment due to problems with delineation of RV contours.

In conclusion, the meta-analysis showed that both LVEF and RVEF were significantly reduced in non-athletic patients with COVID-19 compared with the controls; however, these parameters were not significantly reduced in athletes with COVID-19. Furthermore, various abnormalities, such as LV LGE, pericardial enhancement, and abnormalities in T1 mapping and T2 mapping/T2WI were prevalent, and the occurrence of myocarditis was substantially higher in non-athletes than in athletes.
LVEF (athlete)  
N=3

| Study or Subgroup | COVID-19 | Control | Mean Difference | Mean Difference |
|-------------------|----------|---------|----------------|----------------|
|                   | Mean     | SD      | Total           | IV, Random, 95% Cl |
| Brito_asymptomatic 2021 | 60.3  | 4.9  | 37 | 59.9  | 4.6  | 48 | 30.3% | 0.40 [1.65, 2.45] |
| Clark 2021        | 60.1      | 5.1    | 59 | 60.1  | 5.1   | 56 | 26.9% | 0.00 [2.32, 2.32] |
| Szabó 2021        | 57.4      | 4.4    | 147 | 59.3  | 3.7   | 56 | 43.0% | -2.00 [-3.20, -0.80] |
| Total (95% CI)    | 243       | 131    | 100.0%         | -0.74 [-2.41, 0.93] |

Test for overall effect: Z = 0.87 (p = 0.39)

RVEF (athlete)  
N=3

| Study or Subgroup | COVID-19 | Control | Mean Difference | Mean Difference |
|-------------------|----------|---------|----------------|----------------|
|                   | Mean     | SD      | Total           | IV, Random, 95% Cl |
| Brito_asymptomatic 2021 | 54.6  | 5.9  | 37 | 53.5  | 9.2   | 48 | 26.9% | 1.10 [-2.61, 4.81] |
| Clark 2021        | 53.4      | 4.4    | 59 | 58.7  | 3.7   | 27 | 36.1% | -5.00 [6.79, -3.21] |
| Szabó 2021        | 56.4      | 4.4    | 147 | 57.5  | 5.2   | 56 | 37.1% | -1.00 [-2.54, 0.54] |
| Total (95% CI)    | 243       | 131    | 100.0%         | -1.88 [-5.21, 1.46] |

Test for overall effect: Z = 1.10 (p = 0.27)

Fig. 3 Forest plot of comparison of LVEF and RVEF between athletes with COVID-19 and controls. No significant difference was identified in LVEF (MD = −0.74%, 95% CI = 2.41 to −0.93, p = 0.39) and RVEF (MD = −1.88%, 95% CI = 5.21 to 1.46, p = 0.27). CI confidence interval; COVID-19 coronavirus disease-2019; LVEF left ventricular ejection fraction; MD mean difference; RVEF right ventricular ejection fraction

Fig. 4 Prevalence of cardiac abnormalities on CMR imaging in non-athletes with COVID-19. The prevalence of abnormalities such as LV LGE, pericardial enhancement, T1 mapping, T2 mapping/T2WI, and myocarditis were 27.5% (95%CI 17.4–37.6%), 11.9% (95%CI 4.1–19.6%), 39.5% (95%CI 16.2–62.8%), 38.1% (95%CI 19.0–57.1%). CI confidence interval; CMR cardiac magnetic resonance; COVID-19 coronavirus disease-2019; LGE late gadolinium enhancement; LV left ventricle
Fig. 5 Prevalence of cardiac abnormalities on CMR imaging in athlete COVID-19. The prevalence of abnormalities of LV LGE, pericardial enhancement, T1 mapping, and T2 mapping/T2WI were 10.8% (95%CI 2.3–19.4%), 35.4% (95%CI −3.2 to 73.9%), 5.7% (95%CI −2.9 to 14.2%), 1.9% (95%CI 1.1–2.7%). CI confidence interval; CMR cardiac magnetic resonance; COVID-19 coronavirus disease-2019, LGE late gadolinium enhancement; LV left ventricle

Fig. 6 Prevalence of myocarditis diagnosed by the modified Lake Louise criteria. The prevalence of myocarditis was 17.6% (95%CI 6.3–28.9%) for non-athletes and 0.9% (0.3–1.6%) for athletes
Grant-in-Aid for Young Scientists.

9. Esposito A, Palmisano A, Natale L, Ligabue G, Peretto G, Lovato
7. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoff-
6. Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, Cao S, Liu X, Xiang
4. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R,
3. Hendren NS, Drazner MH, Bozkurt B, Cooper LT Jr (2020)
1. Fauci AS, Lane HC, Redfield RR (2020) Covid-19: navigating the

References

1. Fauci AS, Lane HC, Redfield RR (2020) Covid-19: navigating the uncharted. N Engl J Med 382(13):1268–1269
2. Giustino G, Pinney SP, Lala A, Reddy VY, Johnston-Cox HA, Mechanick JI, Halperin JL, Fuster V (2020) Coronavirus and cardiovascular disease, myocardial injury, and arrhythmia: JACC focus seminar. J Am Coll Cardiol 76(17):2011–2023
3. Hendren NS, Drazner MH, Bozkurt B, Cooper LT Jr (2020) Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation 141(23):1903–1914
4. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234):1417–1418
5. Giustino G, Croft LB, Stefanini GG, Bragato R, Silbiger JJ, Vice- nzi M, Danilov T, Kukar N, Shahan N, Kini A, Camaj A, Bienenstock SW, Rashed ER, Rahman K, Oates CP, Buckley S, Elbaum LS, Arkonac D, Fiter R, Singh R, Raman B, Piechnik SK, Neu-Berkman M, Vehreschild M, Bassily-Marcus AM, Neibart E, Serrao G, Mancini D, Reddy VY, Pinney SP, Dangas G, Blasi F, Sharma SK, Mehran R, Condorelli G, Stone GW, Fuster V, Lerakis S, Goldman ME (2020) Characterization of myocardial injury in patients with COVID-19. J Am Coll Cardiol 76(18):2043–2055
6. Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, Cao S, Liu X, Xiang Y, Zhao Q, Huang H, Yang B, Huang C (2020) Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J 41(22):2070–2079
7. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina A, Escher F, Vasa-Nicotera M, Zerzier AM, Vehechslind M, Nagel E (2020) Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 5(11):1265–1273
8. Brito D, Meester S, Yanamala N, Patel HB, Balck BJ, Casac-clang-Verzosa G, Seetharam K, Rivers D, Beto RJ, Balla S, Monseau AJ, Sengupta PP (2021) High prevalence of pericardial involvement in college student athletes recovering from COVID-19. JACC Cardiovasc Imaging 14(3):541–555
9. Esposito A, Palmisano A, Natale L, Ligabue G, Peretto G, Lovato L, Vignale D, Fiocchi F, Marano R, Russo V (2020) Cardiac magnetic resonance characterization of myocarditis-like acute cardiac syndrome in COVID-19. JACC Cardiovasc Imaging 13(11):2462–2465. https://doi.org/10.1016/j.jcmg.2020.06.003
10. Huang L, Zhao P, Tang D, Zhu T, Han R, Zhan C, Liu W, Zeng H, Tao Q, Xia L (2020) Cardiac involvement in patients recovered from COVID-19 identified using magnetic resonance imaging. JACC 13(11):2330–2339
11. Ng MY, Ferreira VM, Leung ST, Yin Lee JC, Ho-Tung Fong A, To Liu RW, Man Chan JW, Wu AKL, Lung KC, Creaen AM, Fan-Ngai Hung I, Siu CW (2020) Patients recovered from COVID-19 show ongoing subclinical myocarditis as revealed by cardiac magnetic resonance imaging. JACC Cardiovasc Imaging 13(11):2476–2478
12. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutterlet M, Cooper LT, Liu P, Friedman MG (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72(24):3158–3176
13. Theocharis P, Wong J, Pushparajah K, Mathur SK, Simpson JM, Pascall E, Cleary A, Stewart K, Adhvaryu K, Savis A, Kabir SR, Uy MP, Heard H, Peacock K, Miller O (2021) Multimorbidity cardiac evaluation in children and young adults with multisystem inflammation associated with COVID-19. Eur Heart J Cardiovasc Imaging 22(8):896–903
14. Coull AABA (1998) Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat 52:119–126
15. Clark DE, Parikh A, Dendy JM, Diamond AB, George-Durrett K, Fish FA, Slaughter JC, Fitch W, Hughes SG, Soslow JH (2021) COVID-19 myocardial pathology evaluation in athletes with cardiac magnetic resonance (COMPETE CMR). Circulation 143(6):609–612
16. Li X, Wang H, Zhao R, Wang T, Zhu Y, Qian Y, Liu B, Yu Y, Han Y (2021) Elevated extracellular volume fraction and reduced global longitudinal strains in participants recovered from COVID-19 without clinical cardiac findings. Radiology 299(2):E230–E240
17. Malek LA, Marczak M, Milot-Swieczorzek B, Konopka M, Brak- sator W, Drygas W, Krzywański J (2021) Cardiac involvement in consecutive elite athletes recovered from Covid-19: A magnetic resonance study. J Mag Reson Imaging 53(6):1723–1729
18. Pan C, Zhang Z, Luo L, Wu W, Jia T, Lu L, Liu WV, Qin Y, Hu F, Ding X, Qin P, Qian L, Chen J, Li S (2021) Cardiac T1 and T2 mapping showed myocardial involvement in recovered COVID-19 patients initially considered devoid of cardiac damage. J Mag Reson Imaging 54(2):421–428
19. Raisi-Estabragh Z, McCracken C, Cooper J, Fung K, Paiva JM, Khanji MY, Rauuss E, Bisiolelll I, Raman B, Pichocki SK, Nienbauer S, Munroe PB, Harvey NC, Petersen SE (2021) Adverse cardiovascular magnetic resonance phenotypes are associated with greater likelihood of incident coronavirus disease 2019: findings from the UK Biobank. Aging Clin Exp Res 33(4):1133–1144
20. Starekova J, Bludemke DA, Bradham WS, Eckhardt LL, Grist TM, Kusmirek JE, Purtell CS, Schiebler ML, Redder SB (2021) Evaluation for myocarditis in competitive student athletes recovering from coronavirus disease 2019 with cardiac magnetic resonance imaging. JAMA Cardiol 6(8):945–950
21. Wang H, Li R, Zhou Z, Jiang H, Yan Z, Tao X, Li H, Xu L (2021) Cardiac involvement in COVID-19 patients: mid-term follow up by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 23(1):14
22. Joy G, Artico J, Kurdi H, Seraphim A, Lau C, Thornton GD, Oliveira MF, Adam RD, Azimina N, Menacho K, Chacko L, Brown JT, Patel RK, Shihani H, Bhuvu A, Augusto JB, Andiapen M, McKeight A, Noursadeghi M, Pierce I, Evain T, Captur G, Davies RH, Greenwood JP, Fontana M, Kellman P, Schelbert EB, Treibel TA, Manisty C, Moon JC (2021) Prospective case-control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers. JACC Cardiovasc Imaging 14(11):2155–2166
23. Tanaci R, Doebelin P, Götzé C, Zieschang V, Faragali A, Stehning C, Korosoglou G, Erley J, Weiss J, Berger A, Pröpper F, Steinbeis F, Kühne T, Seidel F, Geisel D, Cannon Walter-Rittel T, Stawowy P, Witzenth R, Klingel K, Van Linhout S, Pieske B, Tschope C, Kelle S (2021) COVID-19 vs. classical myocarditis associated myocardial injury evaluated by cardiac magnetic resonance and endomyocardial biopsy. Front Cardiovasc Med 8:737257

24. Rajpal S, Tong MS, Borchers J, Zareba KM, Obarski TP, Simonetti OP, Daniels CJ (2021) Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol 6(1):116–118

25. Urmekena Ulloa J, Martínez de Vega V, Salvador Montañés O, Álvarez Vázquez A, Sánchez-Enrique C, Hernández Jiménez S, Sancho García FD, López Ruiz L, Recio Rodríguez M, Pizarro C, Carnevali Ruiz D, Ángel Cabrera J (2021) Cardiac magnetic resonance in recovering COVID-19 patients. Feature tracking and mapping analysis to detect persistent myocardial involvement. Int J Cardiovasc Health Vasc 36:1054

26. Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalasvaran K, Thornton G, Patel R, Chacko L, Brown JT, Coyle C, Leith D, Shey A, Ariff B, Bell R, Caput G, Coleman M, Goldring J, Gopulan D, Heightman M, Hillman T, Howard L, Jacobs M, Jeetley PS, Kanagaratnam P, Kon OM, Lamb LE, Manisty CH, Mathurdas P, Mayet J, Negus R, Patel N, Pierce L, Russell G, Wollf A, Xue H, Kellman P, Moon JC, Treibel TA, Cole GD, Fontana M (2021) Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Radiol 31(3):E419–e425

27. Galan N, Marchitelli L, Pambianchi G, Catapano F, Cundari G, Birtolo LI, Maestrini V, Mancone M, Fedele F, Catalano C, Francone M (2021) T2-mapping increase is the prevalent imaging biomarker of myocardial involvement in active COVID-19: a Cardiovascular Magnetic Resonance study. J Cardiovasc Magn Reson 23(1):68

28. Kravchenko D, Isaak A, Zimmer S, Mesropyan N, Reinert M, Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalasvaran K, Thornton G, Patel R, Chacko L, Brown JT, Coyle C, Leith D, Shey A, Ariff B, Bell R, Caput G, Coleman M, Goldring J, Gopulan D, Heightman M, Hillman T, Howard L, Jacobs M, Jeetley PS, Kanagaratnam P, Kon OM, Lamb LE, Manisty CH, Mathurdas P, Mayet J, Negus R, Patel N, Pierce L, Russell G, Wollf A, Xue H, Kellman P, Moon JC, Treibel TA, Cole GD, Fontana M (2021) COVID-19 in Wuhan. China JAMA Cardiol 5(7):802–810

29. Liang J, Zhao Q, Huang H, Yang B, Huang C (2020) Association of cardiac injury with mortality in hospitalized patients with COVID-19 infection. J Am Coll Cardiol 75(18):1937–1946

30. Freitas JK, Fayad ZA, Pinney SP, Levin M, Charney A, Bagiella E, Narula J, Glicksberg BS, Mancini DM, Fuster V, Mayet J, Negus R, Patel N, Pierce I, Russell G, Wolff A, Xue H, Kellman P, Moon JC, Treibel TA, Cole GD, Fontana M (2021) Spectrum of cardiac manifestations in COVID-19: a retrospective observational study. Lancet 395(10229):1054–1062

31. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062

32. Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, Zhao S, Somani S, Van Vleck T, Vaid A, Chaudhry F, De Freitas JK, Fayad ZA, Pinney SP, Levin M, Charney A, Bagiella E, Narula J, Glicksberg BS, Nadjakarni G, Mancini DM, Fuster V (2020) Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol 76(5):533–546

33. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C (2020) Association of COVID-19 myocarditis with mortality in hospitalized patients with COVID-19 in Wuhan. China JAMA Cardiol 75(7):802–810

34. Szekely Y, Lichter Y, Taieb P, Botinis E, Howarth D, Boyd RN, D’Souza D, Joannou A, Merdler I, Gal Oz A, Rothschild E, Baruch G, Peri Y, Arbel Y, Topilsky Y (2020) Prevalence of cardiac involvement with COVID-19 in Wuhan. China JAMA Cardiol 5(7):811–818

35. Argulian E, Kurkcuoglu G, Korosoglou G, Erley J, Weiss J, Arbel Y, Topilsky Y (2020) Spectrum of cardiac manifestations in COVID-19: a systemic echocardiographic study. Circulation 142(4):342–353

36. Maceira AM, Prasad SK, Khan M, Pennell DJ (2006) Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. Eur Heart J 27(23):2879–2888

37. Gulati A, Ismail TF, Jabbour A, Alpendurada F, Guha K, Ismail NA, Raza S, Khwaja J, Brown TD, Morarji K, Liodakis E, Br J Sports Med. https://doi.org/10.1136/bjsports-2021-104576

38. Myhre PL, Heck SL, Skranes JB, Prebensen C, Jonassen CM, Bergé T, Mecinaj A, Melles W, Einvik G, Ingul CB, Tveit A, Berdal JE, Røsjø H, Lyngbakken MN, Omland T (2021) Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity. Am Heart J 242:61–70

39. Breitbart P, Koch A, Schmidt M, Magedanz A, Lindhoff-Last E, Voigtlander T, Schmermund A, Mehta RH, Eggebrect H (2021) Prevalence and clinical cardiovascular magnetic resonance findings in post-COVID-19 patients referred for suspected myocarditis. Clin Res Cardiol 110(11):1832–1840

40. Martinez MW, Tucker AM, Bloom OJ, Green G, DiFiori JP, Solomn G, Phelan D, Kim JH, Meeuwsse W, Sills AK, Rowe D, Bocko II, Smith PT, Baggs Gil, Putukian M, Engel DJ (2021) Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening. JAMA Cardiol 6(7):745–752

41. Haaf P, Popp G, Messroghi DR, Broadbent DA, Greenwood JP, Plein S (2016) Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson 18(1):90

42. Kellman P, Moon JC, Treibel TA, Cole GD, Fontana M (2021) Cardiac MRI in patients with prolonged cardiorespiratory symptoms after mild to moderate COVID-19. Radiology 301(3):E419–e425

43. Haaf P, Garg P, Messroghi DR, Broadbent DA, Greenwood JP, Plein S (2016) Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson 18(1):90

44. Szekely Y, Lichter Y, Taieb P, Botinis E, Howarth D, Boyd RN, D’Souza D, Joannou A, Merdler I, Gal Oz A, Rothschild E, Baruch G, Peri Y, Arbel Y, Topilsky Y (2020) Prevalence of cardiac involvement with COVID-19 in Wuhan. China JAMA Cardiol 5(7):811–818

45. Argulian E, Kurkcuoglu G, Korosoglou G, Erley J, Weiss J, Arbel Y, Topilsky Y (2020) Spectrum of cardiac manifestations in COVID-19: a systemic echocardiographic study. Circulation 142(4):342–353

46. Maceira AM, Prasad SK, Khan M, Pennell DJ (2006) Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. Eur Heart J 27(23):2879–2888

47. Gulati A, Ismail TF, Jabbour A, Alpendurada F, Guha K, Ismail NA, Raza S, Khwaja J, Brown TD, Morarji K, Liodakis E, Br J Sports Med. https://doi.org/10.1136/bjsports-2021-104576
Roughton M, Wage R, Pakrashi TC, Sharma R, Carpenter JP, Cook SA, Cowie MR, Assomull RG, Pennell DJ, Prasad SK (2013) The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy. Circulation 128(15):1623–1633

48. Swift AJ, Rajaram S, Campbell MJ, Hurdman J, Thomas S, Capener D, Elliot C, Condliffe R, Wild JM, Kiely DG (2014) Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging 7(1):100–106

49. Kato S, Sekine A, Kusakawa Y, Ogura T, Futaki M, Iwasawa T, Kirigaya H, Gyotoku D, Inuma N, Iguchi K, Nakachi T, Fukui K, Kimura K, Umemura S (2015) Prognostic value of cardiovascular magnetic resonance derived right ventricular function in patients with interstitial lung disease. J Cardiovasc Magn Reson 17(1):10

50. Georgiopoulos G, Figliozzi S, Sanguineti F, Aquaro GD, di Bella G, Stamatelopoulos K, Chiribiri A, Garot J, Masci PG, Ismail TF (2021) Prognostic impact of late gadolinium enhancement by cardiovascular magnetic resonance in myocarditis: a systematic review and meta-analysis. Circ Cardiovasc Imaging 14(1):e011492

51. Fayssoil A, Mustafic H, Mansencal N (2020) The right ventricle in COVID-19 patients. Am J Cardiol 130:166–167

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.